BioMed Realty Commences Tender Offer for Its Exchangeable Notes

SAN DIEGO, Nov. 9 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE:
BMR) today announced that its operating partnership, BioMed Realty, L.P., has
commenced a cash tender offer for any and all of its outstanding 4.50%
Exchangeable Senior Notes due 2026 (the "Notes"). Currently, $107,420,000
aggregate principal amount of the Notes is outstanding. The terms and
conditions are set forth in the offer to purchase and related letter of
transmittal, each dated November 9, 2009.

Pursuant to the tender offer, BioMed is offering to purchase, for cash, any
and all of the outstanding Notes at a purchase price of 100% of the principal
amount of the Notes, plus accrued and unpaid interest up to, but not
including, the date of purchase. The tender offer is scheduled to expire at
midnight, New York City time, on Tuesday, December 8, 2009, unless extended by
BioMed. Tendered Notes may be withdrawn at any time on or prior to the
expiration date of the tender offer. BioMed expects to fund the purchase of
the Notes by drawing on its unsecured line of credit.

This announcement is for informational purposes only and is not an offer to
buy, or the solicitation of an offer to sell, any Notes. The tender offer is
being made solely by and subject to the terms and conditions set forth in a
Schedule TO (including the offer to purchase and related letter of
transmittal) that is being filed by BioMed today with the Securities and
Exchange Commission. The Schedule TO contains important information and should
be read carefully before any decision is made with respect to the tender
offer. The offer to purchase and letter of transmittal are being delivered to
holders of the Notes. Once the Schedule TO and other documents are filed with
the Securities and Exchange Commission, they will be available free of charge
on the Securities and Exchange Commission's website at www.sec.gov.

BioMed has retained Credit Suisse Securities (USA) LLC to serve as the dealer
manager for the tender offer. Questions regarding the tender offer may be
directed to Credit Suisse Securities (USA) LLC at (800) 820-1653 (toll free)
or (212) 538-1862. Requests for documents, free of charge, in connection with
the tender offer may be directed to D.F. King & Co., Inc., the information
agent for the tender offer, at (800) 431-9645 (toll free) or, for banks and
brokers, (212) 269-5550.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on
Providing Real Estate to the Life Science Industry®. The company's tenants
primarily include biotechnology and pharmaceutical companies, scientific
research institutions, government agencies and other entities involved in the
life science industry. BioMed owns or has interests in 69 properties,
representing 114 buildings with approximately 10.5 million rentable square
feet. The company's properties are located predominantly in the major U.S.
life science markets of Boston, San Diego, San Francisco, Seattle, Maryland,
Pennsylvania and New York/New Jersey, which have well-established reputations
as centers for scientific research. Additional information is available at
www.biomedrealty.com.

Forward-Looking Statements

This press release contains forward-looking statements based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These
risks and uncertainties include, without limitation: BioMed's offer to
purchase any and all of the Notes in the tender offer; adverse economic or
real estate developments in the life science industry or in our target
markets, including the ability of our tenants to obtain funding to run their
businesses; our failure to obtain necessary outside financing on favorable
terms or at all, including the continued availability of our unsecured line of
credit; general economic conditions, including downturns in the national and
local economies; volatility in financial and securities markets; defaults on
or non-renewal of leases by tenants; our inability to compete effectively;
increased interest rates and operating costs; our inability to successfully
complete real estate acquisitions, developments and dispositions; risks and
uncertainties affecting property development and construction; our failure to
successfully operate acquired properties and operations; our failure to
maintain our status as a REIT; government approvals, actions and initiatives,
including the need for compliance with environmental requirements; and changes
in real estate, zoning and other laws and increases in real property tax
rates. For a further list and description of such risks and uncertainties, see
the reports filed by the company with the Securities and Exchange Commission,
including the company's most recent annual report on Form 10-K and quarterly
reports on Form 10-Q. Except as required by law, the company disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.

Rick Howe, Director, Corporate Communications of BioMed Realty Trust, Inc.,
+1-858-207-5859